Barclays analyst Steven Valiquette maintained a Hold rating on McKesson (MCK) on August 1 and set a price target of $144. The company’s shares closed on Friday at $148.13, close to its 52-week high of $149.99.
According to TipRanks.com, Valiquette is a 4-star analyst with an average return of 6.5% and a 53.8% success rate. Valiquette covers the Services sector, focusing on stocks such as AmerisourceBergen Corporation, Molina Healthcare, and Tenet Healthcare.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for McKesson with a $152.60 average price target, a 3.0% upside from current levels. In a report issued on July 22, Guggenheim also initiated coverage with a Hold rating on the stock with a $152 price target.
See today’s analyst top recommended stocks >>
Based on McKesson’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $55.73 billion and net profit of $423 million. In comparison, last year the company earned revenue of $52.61 billion and had a GAAP net loss of $138 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
McKesson Corp. engages in the provision of supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. It operates through the following segments: U.S. Pharmaceutical and Specialty Solutions; European Pharmaceutical Solutions; Medical-Surgical Solutions and Other.
